MichaelT.JarrattMD

Dermatology • Austin, TX

Principal Investigator, DermResearch, Inc, Austin, TX

Join to view full profile

Dr. Jarratt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jarratt's full profile

Already have an account?

Office
8140 N Mopac Expy
Ste 3-130
Austin, TX 78759
Phone+1 512-345-1350

Education & Training

Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's HospResidency, Dermatology, 1969 - 1972
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1966 - 1967
University of Texas Southwestern Medical SchoolClass of 1966

Certifications & Licensure

TX State Medical License 1966 - 2019

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Start of enrollment: 2007 Jan 01
Completed
Phase 2
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
Completed
Phase 2
Treatment of Androgenetic Alopecia in Females, 9 Beam Start of enrollment: 2009 Oct 01
Completed
Not Applicable
Safety Study of Cosmetic Tissue Augmentation in People of Color Start of enrollment: 2009 Mar 01
Completed
Not Applicable
Dose Response Study of Patients With Erythematous Rosacea Start of enrollment: 2010 Aug 01
Completed
Phase 2
Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds Start of enrollment: 2010 Sep 01
Completed
Not Applicable
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 May 01
Completed
Phase 3
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
Completed
Phase 3
Study of A-101 for the Treatment of Seborrheic Keratosis Start of enrollment: 2014 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

34 citations
Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
Warren W. Piette, Susan C. Taylor, David M. Pariser, Michael Jarratt, Pranav B. Sheth
Archives of Dermatology. 2008-12-15
10 citations
Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis.
Lawrence Anderson, Michael Jarratt, George J. Schmieder, Stephen Shumack, Janelle Katsamas
The Journal of Clinical and Aesthetic Dermatology. 2014-12-01
46 citations
Progressive nodular histiocytoma.
O. David Taunton, Daniel Yeshurun, Michael Jarratt
Archives of Dermatology. 1978-10-01